Stock·NYSE·Healthcare
Medtronic (MDT)
- Market cap
- $121.20B
- P/E
- 23.28
- Dividend yield
- 3.02%
- Street target
- $106.00median of 29 analysts
- 52-week range
- $73.31 $106.33
The short version
Where MDT stands today, in four lines, and what CleaRank Financial AI makes of it.
MDT at a glance
Medtronic (MDT): Strong Buy, 84/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($90.89 and $88.30).
- Earnings MDT beat estimates in 4 of its last 4 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $9.7M and bought $463K over the last 18 months.
- Valuation P/E of 23.3 against 31.9 for the Healthcare sector: a discount to peers (-27%).
Figures as of October 18, 2026.
CleaRank Financial AI
CleaRank rates Medtronic (MDT) Strong Buy, with a model score of 84/100.
The trend lifts the score most: the price is 7.30% above its 200-day average and 4.25% above its 50-day average, and the 50-day average is 2.93% above the 200-day. The 50-day average stands at $90.89 and the 200-day at $88.30. Over the past year the price fell 0.31%.
Only on CleaRank
Figures we compute ourselves from MDT's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $94.75 is 4.2% above the 50-day simple moving average of $90.89.Price above its 200-day average ›
The price is 7.3% above the 200-day simple moving average of $88.30.50-day average above the 200-day ›
The 50-day average ($90.89) is 2.9% above the 200-day average ($88.30), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 65% of its 52-week range, between $73.31 and $106.33.
MDT share price
Pick a period: each tab shows how far MDT has moved over it, to the last close.
Today's trading
Where MDT sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 23.28 is 27.0% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 3.23 is 5.0% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $5.2B on revenue of $37.5B, a net margin of 13.9%.Beat estimates in most recent reports ›
MDT beat the EPS estimate in 4 of its last 4 reports.Pays a dividend ›
The trailing dividend yield is 3.02%, or $2.86 a share a year.
Key statistics
The headline figures for MDT.
As of October 18, 2026, MDT trades at $94.75, with a market value of $121.20B, a P/E ratio of 23.28 and a dividend yield of 3.02%.
What the numbers say
CleaRank Financial AI's reading of MDT's valuation, growth and risks.
Medtronic (MDT) carries a trailing P/E of 23.28, which is 27.0% below the Healthcare sector median of 31.9. The peer comparison on this page labels that a discount to peers. Measured against sales, the P/S of 3.23 sits 5.0% under the sector median of 3.4. The company has a market capitalisation of $121.2B and trailing earnings of $4.07 per share.
In the latest year revenue grew 13.70%, 5.6 percentage points faster than the sector median of 8.1%. Margins stand at a net margin of 13.93% and an operating margin of 19.33%. It generates a return on equity of 10.65%, above the sector median of 7.3%. Debt-to-equity of 0.55 and a trailing dividend yield of 3.02% ($2.86 a share a year) round out the fundamentals.
The September 1, 2026 report came in ahead of forecasts, beating the estimate by 4.32%. Earnings per share were $1.45 against an expected $1.39. In the session that followed, the shares climbed 0.15%.
Across its last 4 reports, MDT beat the estimate every time; even so, 1 of those 4 beats was followed by a lower share price the next session. Earlier, the stock fell 4.15% after the May 21, 2025 report, a beat of 2.53%. Looking ahead, analysts expect EPS of $5.98 this fiscal year (growth of 8.0%) and $6.41 the year after (growth of 7.2%).
Day-to-day volatility is the first thing to plan around: MDT has moved 1.51% on an average session.
MDT against the Healthcare sector
How MDT compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: MDT trades at a notable discount to sector peers (-27%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 6, 2025, MDT has gained 15.1% against a gain of 31.6% for XLV.
Performance against XLV
MDT and the Healthcare sector fund over the same days.
Revenue and earnings
How much MDT sells, and how much of it becomes profit.
Revenue growth: Revenue grew 8.4% in FY2026 to $36.4B, from $33.5B a year earlier.
Profit margin: The net margin was 13.3% in FY2026, down from 14.0% the year before.
Profitable: MDT earned $4.8B in FY2026.
Earnings reality check
Did MDT beat what analysts expected, and how did the stock react?
Earnings record: MDT beat the analyst estimate in 4 of the last 4 quarters.
Market reaction: The stock fell in the first session after 1 of those 4 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Sep 1, 2026after close | $1.39 | $1.45 | +4.32% | +0.15% | -0.16% |
| Feb 17, 2026after close | $1.34 | $1.36 | +1.49% | +2.16% | +0.35% |
| Aug 19, 2025after close | $1.23 | $1.26 | +2.44% | +3.69% | +2.54% |
| May 21, 2025after close | $1.58 | $1.62 | +2.53% | -4.15% | -2.37% |
As of October 18, 2026, MDT has beaten the analyst EPS estimate in 4 of its last 4 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on September 1, 2026, came in 4.32% above the estimate and the stock moved +0.15% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 64.1, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 64.1 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of MDT
The score, the reasoning behind it, and what could move the price next.
Medtronic (MDT) is trading in an uptrend. The stock sits at $94.75, which is 4.25% above its 50-day average of $90.89 and 7.30% above its 200-day average of $88.30. That 50-day average is in turn 2.93% above the 200-day. Across the 52-week range, from $73.31 up to $106.33, the price is at 65% of the way up.
Recent gains sit against a weaker longer record: the price rose 2.32% over the past month, rose 13.88% over the past three months and fell 0.31% over the past year. On momentum, the 14-day RSI reads 64.1, in the bullish zone, below the overbought line, with the MACD line positive. The price fell 0.73% in the last session on volume 38.0% below its average.
Earnings beat ›
The September 1, 2026 report beat the EPS estimate by 4.32%, and the share price rose 0.15% in the first session after it.
Source: Earnings report, September 1, 2026Rating reaffirmed ›
BTIG kept its Buy rating on October 12, 2026.
Source: Analyst action, BTIG, October 12, 2026
New analyst coverage ›
Barclays started coverage at Equal-Weight on October 7, 2026.
Source: Analyst action, Barclays, October 7, 2026
- Keep an eye on two levels: the 52-week high at $106.33, which lies above the price, and the 50-day SMA at $90.89, which lies below it.
- The 14-day RSI reads 64.1, in the bullish zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- The share price climbed 0.15% in the first session after the September 1, 2026 report, and MDT has beaten estimates in 4 of the last 4 reports.
MDT trades above its 50-day and 200-day moving averages ($90.89 and $88.30), which is what makes the trend up; losing the 50-day would be the first warning. The nearest level under the price is the 50-day SMA at $90.89.
The 52-week high at $106.33 is the next level overhead. The RSI sits in the bullish band, which supports the current direction without being stretched.
Technical indicators
Momentum and trend for MDT, from its daily closes.
As of October 18, 2026, with MDT at $94.75, its 14-day RSI is 64.1 (showing bullish momentum without being overbought), its 50-day simple moving average is $90.89 and its 200-day is $88.30.
Calculated by CleaRank on daily closes as of October 18, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What MDT moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 18, 2026, MDT's 1-year correlation of daily returns is +0.26 with S&P 500 (SPY), +0.11 with Nasdaq 100 (QQQ), -0.02 with Bitcoin (BTC) and +0.07 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
19 of 29 analysts rate it a buy or strong buy, 10 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $106.00 is 11.9% above the price.More buy ratings than three months ago ›
19 of 29 rate it a buy now, against 19 of 29 three months ago.
MDT Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 12, 2026 | BTIG | Maintains | Buy |
| Oct 7, 2026 | Barclays | Initiates | Equal-Weight |
| Sep 30, 2026 | TD Cowen | Reiterates | Buy |
| Sep 3, 2026 | UBS | Maintains | Buy |
| Sep 2, 2026 | Truist Securities | Reiterates | Hold |
| Sep 2, 2026 | Wells Fargo | Maintains | Overweight |
As of October 18, 2026, 29 Wall Street analysts cover MDT: 19 rate it a buy or strong buy, 10 a hold and 0 a sell or strong sell. Their 12-month price targets range from $85.00 to $121.00, with a median of $106.00, 11.9% above the price of $94.75.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
MDT trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from MDT's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much MDT tends to move, against the market and on its own.
The long record
MDT's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.51% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 44.2%, from September 2021 to October 2023; the price is still 17.5% below that peak.Most 1-year holds ended higher ›
65% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $14,818, against $41,793 in the S&P 500 (SPY).
MDT Drawdowns & Recovery
As of October 18, 2026, MDT's worst peak-to-trough fall over the last 10 years with dividends reinvested was -44.2% (September 2021 to October 2023); it is still 17.5% below that peak, and 65% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into MDT in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: MDT trailed the S&P 500 over this period: $14,818 against $41,793.
A $10,000 investment in MDT in October 2016 would be worth about $14,818 today with dividends reinvested, compared with about $41,793 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to MDT, and which have not.
Strongest month, January: an average of +4.11%, up in 8 of 10 years.
Weakest month, March: an average of -2.11%, up in 3 of 10 years.
This month, October: has averaged -2.04%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, MDT's strongest calendar month has been January (average +4.11%, up in 8 of 10 years) and its weakest March (average -2.11%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in MDT, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in MDT today could grow to about $14,554 by 2036 in the base case, with a 90th-percentile outcome near $38,011 and a 10th-percentile outcome around $5,572. The simulation models price only; at today's 3.02% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
MDT Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $110 for MDT by 2030 in the base case, from $94.75 today (1.2x over 4 years). The 10th-percentile path ends near $59.99. These are outcomes of a Monte Carlo simulation run on MDT's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $72.62 | $98.37 | $133 | |
| 2028 | $66.48 | $102 | $157 | |
| 2029 | $62.68 | $106 | $179 | |
| 2030 | $59.99 | $110 | $202 | |
| 2031 | $57.97 | $114 | $225 |
Method: a lognormal simulation of MDT's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
MDT insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $463K on the open market and sold $9.7M.
As of October 18, 2026, MDT insiders reported 6 open-market sales worth $9.7M and 1 open-market purchase worth $463K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 16, 2026 | Harry Skip Kiil
Officer
|
Sell | 1.5K | $138.9K |
| Sep 15, 2026 | Denise L Blomquist
Officer
|
Grant | 600 | - |
| Aug 3, 2026 | Denise L Blomquist
Officer
|
Grant | 2.3K | - |
| Aug 3, 2026 | Harry Skip Kiil
Officer
|
Grant | 9.2K | - |
| Aug 3, 2026 | Michael Marinaro
Officer
|
Grant | 57.1K | - |
| Aug 3, 2026 | Geoffrey S Martha
Chief Executive Officer
|
Grant | 41.5K | - |
| Aug 3, 2026 | Thierry Jean Louis Pieton
Chief Financial Officer
|
Grant | 11.5K | - |
| Aug 3, 2026 | Michelle Quinn
General Counsel
|
Grant | 6.3K | - |
| Aug 3, 2026 | Kweli Thompson
Officer
|
Grant | 6.9K | - |
| Aug 3, 2026 | Matthew R. Walter
Officer
|
Grant | 5.8K | - |
| Jul 8, 2026 | Matthew R. Walter
Officer
|
Sell | 3.1K | $257.9K |
| Jun 8, 2026 | Harry Skip Kiil
Officer
|
Sell | 4.2K | $337.0K |
| May 26, 2026 | Denise L Blomquist
Officer
|
Grant | 1.7K | - |
| May 26, 2026 | Harry Skip Kiil
Officer
|
Grant | 15.2K | - |
| May 26, 2026 | Michael Marinaro
Officer
|
Grant | 19.0K | - |
| May 26, 2026 | Geoffrey S Martha
Chief Executive Officer
|
Grant | 95.0K | - |
| May 26, 2026 | Brett A Wall
Officer
|
Grant | 26.9K | - |
| May 26, 2026 | Matthew R. Walter
Officer
|
Grant | 9.1K | - |
| Apr 27, 2026 | Craig Arnold
Director
|
Grant | 2.1K | - |
| Apr 27, 2026 | Denise L Blomquist
Officer
|
Grant | 1.5K | - |
| Apr 27, 2026 | Scott C Donnelly
Director
|
Grant | 2.1K | - |
| Apr 27, 2026 | Lidia Ph.d. Fonseca
Director
|
Grant | 2.1K | - |
| Apr 27, 2026 | John P Groetelaars
Director
|
Grant | 1.4K | - |
| Apr 27, 2026 | Randall J Hogan III
Director
|
Grant | 2.1K | - |
| Apr 27, 2026 | William R Jellison
Director
|
Grant | 1.4K | - |
| Apr 27, 2026 | Joon Sup Lee
Director
|
Grant | 1.8K | - |
| Apr 27, 2026 | Gregory P Lewis
Director
|
Grant | 2.1K | - |
| Apr 27, 2026 | Kevin E Lofton
Director
|
Grant | 2.1K | - |
| Apr 27, 2026 | Elizabeth G Nabel
Director
|
Grant | 2.1K | - |
| Apr 27, 2026 | Kendall J Powell
Director
|
Grant | 2.1K | - |
| Feb 20, 2026 | Denise L Blomquist
Officer
|
Grant | 340 | - |
| Feb 19, 2026 | Harry Skip Kiil
Officer
|
Sell | 52.5K | $5.1M |
| Feb 19, 2026 | Harry Skip Kiil
Officer
|
Option | 50.9K | $4.6M |
| Nov 20, 2025 | Denise L Blomquist
Officer
|
Grant | 170 | - |
| Nov 19, 2025 | Gregory L Smith
Officer
|
Sell | 30.0K | $3.1M |
| Sep 3, 2025 | Harry Skip Kiil
Officer
|
Sell | 8.6K | $788.0K |
| Aug 25, 2025 | William R Jellison
Director
|
Buy | 5.0K | $462.8K |
| Aug 1, 2025 | Denise L Blomquist
Officer
|
Option | 518 | $16.7K |
| Aug 1, 2025 | Harry Skip Kiil
Officer
|
Grant | 10.5K | - |
| Aug 1, 2025 | Michael Marinaro
Officer
|
Option | 9.7K | $243.8K |
| Aug 1, 2025 | Geoffrey S Martha
Chief Executive Officer
|
Option | 98.3K | $3.2M |
| Aug 1, 2025 | Gregory L Smith
Officer
|
Grant | 11.3K | - |
| Aug 1, 2025 | Brett A Wall
Officer
|
Grant | 15.2K | - |
| Aug 1, 2025 | Matthew R. Walter
Officer
|
Option | 3.1K | $75.1K |
| Jul 28, 2025 | Denise L Blomquist
Officer
|
Grant | 2.2K | - |
| Jul 28, 2025 | Harry Skip Kiil
Officer
|
Grant | 7.6K | - |
| Jul 28, 2025 | Michael Marinaro
Officer
|
Grant | 9.8K | - |
| Jul 28, 2025 | Geoffrey S Martha
Chief Executive Officer
|
Grant | 37.5K | - |
| Jul 28, 2025 | Thierry Jean Louis Pieton
Chief Financial Officer
|
Grant | 8.7K | - |
| Jul 28, 2025 | Michelle Quinn
General Counsel
|
Grant | 21.7K | - |
| Jul 28, 2025 | Gregory L Smith
Officer
|
Grant | 9.8K | - |
| Jul 28, 2025 | Brett A Wall
Officer
|
Grant | 9.8K | - |
| Jul 28, 2025 | Matthew R. Walter
Officer
|
Grant | 4.4K | - |
| Jun 3, 2025 | Denise L Blomquist
Officer
|
Grant | 310 | - |
| Apr 28, 2025 | Craig Arnold
Director
|
Grant | 2.1K | $175.1K |
| Apr 28, 2025 | Denise L Blomquist
Officer
|
Grant | 3.0K | - |
| Apr 28, 2025 | Scott C Donnelly
Director
|
Grant | 2.1K | $175.1K |
| Apr 28, 2025 | Lidia Ph.d. Fonseca
Director
|
Grant | 2.1K | $175.1K |
| Apr 28, 2025 | Andrea Jo Goldsmith
Director
|
Grant | 2.1K | $175.1K |
| Apr 28, 2025 | Randall J Hogan III
Director
|
Grant | 2.1K | $175.1K |
| Apr 28, 2025 | Gregory P Lewis
Director
|
Grant | 2.1K | $175.1K |
| Apr 28, 2025 | Kevin E Lofton
Director
|
Grant | 2.1K | $175.1K |
| Apr 28, 2025 | Elizabeth G Nabel
Director
|
Grant | 2.1K | $175.1K |
| Apr 28, 2025 | Kendall J Powell
Director
|
Grant | 2.1K | $175.1K |
Source: TwelveData, from reported insider filings
Questions people ask
Answered from the figures on this page, as of October 18, 2026.